Generated by AI
Adagio Medical Holdings, Inc. is a medical technology company focused on developing and commercializing catheter-based ablation systems for the treatment of cardiac arrhythmias. Its current portfolio includes the iCLAS atrial ultra-low temperature ablation system, the vCLAS ventricular ultra-low temperature catheter platform, and Cryopulse pulsed field cryoablation catheters. These technologies are designed to support physicians treating rhythm disorders such as atrial fibrillation and ventricular tachycardia, with an emphasis on delivering targeted lesion creation in cardiac tissue. Adagio Medical Holdings, Inc. operates as a healthcare device company serving the electrophysiology market, where catheter ablation plays an important role in minimally invasive heart rhythm management. Headquartered in Laguna Hills, California, the company concentrates on clinical and commercial use cases across cardiac arrhythmia care.
Website26051 Merit Circle
Laguna Hills, CA, 92653
United States
The latest articles about ADGM.
LAGUNA HILLS, Calif., November 16, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2026.
Summary of Nov 16's posts. Generated by AI.
Summary of Oct 2's posts. Generated by AI.
Adagio Medical (NASDAQ:ADGM) has begun a formal strategic review that could include a sale, merger or other transaction, while reducing its workforce and continuing to advance the U. S.
Summary of Oct 6's posts. Generated by AI.
Investors talking about ADGM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.